reliance on sales in China. At present, the Company’s products are well- received in the Philippines but still could not make up for the slowdown in sales in China. The Company is committed to expanding

ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than

reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16

its revenue streams which mitigate the risk of reliance on sales in China. At present, the Company’s products are well - received in the Philippines but still could not make up for the slowdown in sales

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

customer base and diversify its revenue streams which mitigate the risk of reliance on sales in China. At present, the Company’s products are well - received in the Philippines but still could not make up

สะสมที่ลดลงจากผลกระทบของการเปลี่ยนแปลงนโยบายการบัญชี ฉบับที่ 9 และฉบับที่ 16 จำนวน 8 ล้าน บาท (one-time adjust) ณ วันที่ 31 มีนาคม 2563 อัตราหนี้สินต่อส่วนของผู้ถือหุ้นของกลุ่มบริษัทฯ (D/E ratio) เท่ากับ

a Private Visit to facilitate those who need to visit the project. In this regard, the Company will closely monitor the situation of COVID-19 and continuously adjust the operation pattern to keep up

. The New Normal will also make the Company to adjust its strategy to implement its 3 business groups faster. For the Online Top-Up & Payment Business, the Company continually focuses on adding new